IQVIA (NYSE:IQV) Given New $210.00 Price Target at Citigroup

IQVIA (NYSE:IQV - Get Free Report) had its price objective dropped by stock analysts at Citigroup from $225.00 to $210.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the medical research company's stock. Citigroup's price target suggests a potential upside of 12.88% from the company's previous close.

A number of other brokerages have also issued reports on IQV. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Bank of America reduced their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Trading Up 1.3 %

Shares of IQVIA stock traded up $2.47 during trading on Tuesday, hitting $186.04. The stock had a trading volume of 1,050,048 shares, compared to its average volume of 1,208,733. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $32.80 billion, a PE ratio of 24.81, a P/E/G ratio of 1.99 and a beta of 1.50. The stock has a 50 day simple moving average of $198.24 and a 200 day simple moving average of $213.66. IQVIA has a 1 year low of $179.28 and a 1 year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IQV. Siemens Fonds Invest GmbH raised its holdings in shares of IQVIA by 973.2% during the 4th quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company's stock valued at $4,195,000 after buying an additional 19,356 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of IQVIA during the fourth quarter valued at approximately $25,152,000. Forum Financial Management LP raised its holdings in shares of IQVIA by 53.2% during the fourth quarter. Forum Financial Management LP now owns 2,067 shares of the medical research company's stock valued at $406,000 after acquiring an additional 718 shares in the last quarter. Toronto Dominion Bank grew its stake in IQVIA by 2.2% in the fourth quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company's stock worth $12,139,000 after purchasing an additional 1,358 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in IQVIA in the fourth quarter worth $841,000. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.